CDER Conversation Focuses on OPDP’s Efforts to Help Ensure Prescription Drug Promotion Is Truthful, Balanced and Accurate - Drug Information Update

If your email program has trouble displaying this email, view it as a web page. CDER Conversation Focuses on OPDP's Efforts to Help Ensure Prescription Drug Promotion is Truthful, Balanced and Accurate FDA's Center for Drug Evaluation and Research's (CDER) Office of Prescription Drug Promotion (OPDP) works to help ensure that prescription drug promotion is truthful and not misleading. It does so through comprehensive surveillance, compliance, policy, and education programs. The office also fosters better communication of drug labeling and promotional information to health care providers and the public. In this CDER Conversation, Katie Gray, Pharm.D., acting OPDP director, speaks about the office's 2020 achievements and 2021 goals, its COVID-19 response, and the ways OPDP continues to streamline operations to fulfill its public health mission. Learn More This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA